Wall Street analysts forecast that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report $24.66 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with the highest sales estimate coming in at $35.09 million and the lowest estimate coming in at $16.96 million. Lexicon Pharmaceuticals reported sales of $13.75 million in the same quarter last year, which indicates a positive year-over-year growth rate of 79.3%. The business is expected to issue its next quarterly earnings results on Monday, July 29th.

On average, analysts expect that Lexicon Pharmaceuticals will report full year sales of $92.62 million for the current fiscal year, with estimates ranging from $59.31 million to $175.35 million. For the next year, analysts forecast that the business will post sales of $103.80 million, with estimates ranging from $39.98 million to $154.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.21). The firm had revenue of $9.20 million during the quarter, compared to analyst estimates of $13.26 million. During the same quarter in the previous year, the business posted ($0.40) earnings per share. Lexicon Pharmaceuticals’s revenue for the quarter was down 63.8% compared to the same quarter last year.

LXRX has been the topic of a number of analyst reports. Needham & Company LLC raised their price objective on shares of Alteryx to $108.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Gabelli raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 25th. Wedbush set a $175.00 target price on shares of Lululemon Athletica and gave the company a “hold” rating in a report on Tuesday, June 11th. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Finally, ValuEngine downgraded shares of Wolverine World Wide from a “hold” rating to a “sell” rating in a report on Monday, May 20th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $16.38.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Paloma Partners Management Co acquired a new position in Lexicon Pharmaceuticals during the fourth quarter worth about $73,000. First Manhattan Co. purchased a new stake in Lexicon Pharmaceuticals in the first quarter valued at approximately $15,282,000. Clearbridge Investments LLC grew its holdings in Lexicon Pharmaceuticals by 3.4% in the first quarter. Clearbridge Investments LLC now owns 1,292,130 shares of the biopharmaceutical company’s stock valued at $7,184,000 after purchasing an additional 42,540 shares during the period. Geode Capital Management LLC grew its holdings in Lexicon Pharmaceuticals by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 565,085 shares of the biopharmaceutical company’s stock valued at $3,752,000 after purchasing an additional 13,664 shares during the period. Finally, Gamco Investors INC. ET AL grew its holdings in Lexicon Pharmaceuticals by 10.0% in the first quarter. Gamco Investors INC. ET AL now owns 22,000 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 98.27% of the company’s stock.

Shares of LXRX traded up $0.17 during midday trading on Monday, reaching $5.45. The stock had a trading volume of 265,687 shares, compared to its average volume of 685,128. Lexicon Pharmaceuticals has a 1-year low of $4.25 and a 1-year high of $13.13. The business has a fifty day moving average price of $5.88. The firm has a market capitalization of $579.18 million, a P/E ratio of -4.78 and a beta of 0.84.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Read More: What is the role of the G-20?

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.